{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=.9+normal+saline&page=8",
    "query": {
      "intervention": ".9 normal saline",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 220,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=.9+normal+saline&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=.9+normal+saline&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T06:08:47.940Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01129453",
      "title": "Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Salmonella"
      ],
      "interventions": [
        {
          "name": "CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 51,
      "start_date": "2010-05",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2021-04-30",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129453"
    },
    {
      "nct_id": "NCT02369068",
      "title": "Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pelvic Pain"
      ],
      "interventions": [
        {
          "name": "Onabotulinumtoxin A",
          "type": "DRUG"
        },
        {
          "name": "Kenalog",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jamie Bartley, DO",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 21,
      "start_date": "2015-08",
      "completion_date": "2018-09-24",
      "has_results": true,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02369068"
    },
    {
      "nct_id": "NCT01515943",
      "title": "Convergence Insufficiency Treatment Study (CITS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Convergence Insufficiency"
      ],
      "interventions": [
        {
          "name": "Active home-based computer vergence/accommodative therapy",
          "type": "OTHER"
        },
        {
          "name": "Near target push-ups",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo home-based computer vergence/accommodative therapy",
          "type": "OTHER"
        },
        {
          "name": "Placebo yoked prism flippers",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "9 Years to 17 Years"
      },
      "enrollment_count": 204,
      "start_date": "2012-06",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 2,
      "location_summary": "Cranberry TWP, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Cranberry TWP",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01515943"
    },
    {
      "nct_id": "NCT05575492",
      "title": "A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus"
      ],
      "interventions": [
        {
          "name": "mRNA-1647",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "9 Years to 25 Years"
      },
      "enrollment_count": 873,
      "start_date": "2022-11-07",
      "completion_date": "2026-05-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 44,
      "location_summary": "La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05575492"
    },
    {
      "nct_id": "NCT04173819",
      "title": "Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "3BNC117-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 225,
      "start_date": "2019-01-25",
      "completion_date": "2023-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173819"
    },
    {
      "nct_id": "NCT05909709",
      "title": "Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Facet Joints; Degeneration",
        "Back Pain",
        "Facet Joint Pain"
      ],
      "interventions": [
        {
          "name": "Alocyte low dose",
          "type": "DRUG"
        },
        {
          "name": "Alocyte medium dose",
          "type": "DRUG"
        },
        {
          "name": "Alocyte high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alimorad Farshchian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-04-29",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 1,
      "location_summary": "North Miami, Florida",
      "locations": [
        {
          "city": "North Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05909709"
    },
    {
      "nct_id": "NCT01147406",
      "title": "Safety and Tolerability Study of N6022 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "N6022",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nivalis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 41,
      "start_date": "2010-08",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2014-03-07",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147406"
    },
    {
      "nct_id": "NCT00811577",
      "title": "A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scar Prevention",
        "Scar Reduction"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AZX100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Capstone Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 150,
      "start_date": "2009-01",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2012-10-11",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 5,
      "location_summary": "Pasadena, California • DeLand, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811577"
    },
    {
      "nct_id": "NCT00105183",
      "title": "EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary",
        "Idiopathic Pulmonary Fibrosis",
        "Cystic Fibrosis",
        "Bronchiectasis",
        "Pulmonary Vascular Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EZ-2053",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EZ-2053 5mg/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Neovii Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 223,
      "start_date": "2005-01",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2012-06-11",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00105183"
    },
    {
      "nct_id": "NCT01432626",
      "title": "Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress Induced Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "I-123 radiolabeled metaiodobenzylguanidine cardiac imaging",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-09",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-22",
      "last_synced_at": "2026-10-14T06:08:47.940Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01432626"
    }
  ]
}